期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Clinical evaluation of the first domestically produced generic isosulfan blue injection in sentinel lymph node biopsy for early breast cancer in China:a multicenter,single-arm,open validation trial(CSBrS-024) 被引量:1
1
作者 fengjiang qu Di Wu +9 位作者 Yunjiang Liu Wei Gao Shu Wang Siyuan Wang Feng Jin Bo Chen Jian Huang Shanshan Sun Zhimin Fan Chinese Society of Breast Surgery 《Chinese Medical Journal》 SCIE CAS CSCD 2022年第14期1753-1755,共3页
In 2020,the first generic isosulfan blue product for injection(notification number:2020 LP00901,batch number:118210301,5 mL:50 mg,Guangdong Hebo Pharmaceutical Co.,Ltd.)was approved by the National Medical Products Ad... In 2020,the first generic isosulfan blue product for injection(notification number:2020 LP00901,batch number:118210301,5 mL:50 mg,Guangdong Hebo Pharmaceutical Co.,Ltd.)was approved by the National Medical Products Administration of China.This multicenter,single-arm,phase III,open clinical validation trial was organized by the Chinese Society of Breast Surgery to evaluate the efficacy and safety of this domestically produced generic isosulfan blue injection for sentinel lymph node biopsy(SLNB)in patients with early breast cancer(BC)in China. 展开更多
关键词 INJECTION BIOPSY Surgery
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部